Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus (T2DM)

Study identifier:MB102-066

ClinicalTrials.gov identifier:NCT01165268

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Dapagliflozin

Sex

All

Actual Enrollment

24

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Aug 2010
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria